Drug industry
Article Abstract:
The larger companies in the drug industry have continued their 1997 economic performance during the 1st qtr of 1998, and have seen higher earnings and sales, due to an aging population and other factors. Industry stock prices have increased, as well, and earnings are expected to increase by 15% in 1998 and 14% in 1999. However, these stocks are not attractive to investors for the next three to five years as they are at historic highs in 1998.
Author: Rho, George, Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Feenan, Gerard, Harris, Frederick L., III, Clark, Charles, Gallen, David, Markey, Keith A., Ferguson, Keith E., DaSilva, Mark W., Gagas, Adam C., Owens, Victoria, Wolfsdorf, Ronan T.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1998
Finance, SmithKline Beecham Group PLC, ICN, Valeant Pharmaceuticals International, Jones Medical Industries Inc., Neurex Corp., R.P. Scherer Corp., SHR, Immunetech Pharmaceuticals Inc.
Drug industry
Article Abstract:
The international pharmaceutical industry continues to score high on timeliness, fueled by new products and fresh marketing ideas in spite of the economic downturn in Asia and Eastern Europe. Companies such as Warner-Lambert and Eli Lilly led earnings growth in the 3d qtr 1998. Over the long term, investors should be careful about buying these stocks because of their high P/E rations.
Author: Rho, George, Mitkowski, Robert, Jr., Ferro, Mario, Romaine, Sigourney B., Clark, Charles, Gallen, David, Butler, Jeremy J., Markey, Keith A., Gagas, Adam C., Owens, Victoria
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1998
Research and Development in the Physical, Engineering, and Life Sciences, Genetic Engineering, Biotechnology industry, Biotechnology industries, Securities, SmithKline Beecham PLC, Covance Inc., Dura Pharmaceuticals Inc., Inhale Therapeutic Systems Inc., Jones Pharma Inc., Pharmaceutical Product Development Inc., CVD, DURA, INHL, PPDI, Genzyme General Div., ICN Pharmaceuticals
Subjects list: Pharmaceutical industry, Drugs, Eli Lilly and Co., Pfizer Inc., Monsanto Co., Pharmacia and Upjohn Inc., MTC, PNU, Glaxo Wellcome PLC, Genentech Inc., Warner-Lambert Co., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Block Drug Company Inc., Chiron Corp., Cygnus Inc., Forest Laboratories Inc., Human Genome Sciences Inc., Immunex Corp., IVAX Corp., Mylan Laboratories Inc., Perrigo Co., Quintiles Transnational Corp., Schering-Plough Corp., Sicor Inc., Watson Pharmaceuticals Inc., AZA, AHP, AMGN, BRL, BGEN, BLOCA, BMY, CHIR, FRX, HGSI, IMNX, IVX, JMED, LLY, MLY, PRGO, PFE, QTRN, SGP, WLA, GNE, Wyeth, Merck & Company Inc., Agouron Pharmaceuticals Inc., AGPH, Barr Laboratories Inc., Roberts Pharmaceutical Corp., RPCX, GNSA, WATS
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
